Viewing Study NCT00005605



Ignite Creation Date: 2024-05-05 @ 10:00 AM
Last Modification Date: 2024-10-26 @ 9:05 AM
Study NCT ID: NCT00005605
Status: COMPLETED
Last Update Posted: 2011-02-21
First Post: 2000-05-02

Brief Title: Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer
Sponsor: Northwestern University
Organization: Northwestern University

Study Overview

Official Title: Does Tamoxifen Prevent the Skeletal and Cardiovascular Morbidity of Chemotherapy in Premenopausal Women
Status: COMPLETED
Status Verified Date: 2011-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Tamoxifen may be able to increase bone density and decrease cholesterol in women who are undergoing chemotherapy for breast cancer

PURPOSE Clinical trial to study the effectiveness of tamoxifen in preventing bone loss and heart disease caused by chemotherapy treatment in premenopausal women who have stage I or stage II breast cancer
Detailed Description: OBJECTIVES

Compare the bone density in the femoral neck and lumbar spine and cholesterol levels in premenopausal women with stage I or II breast cancer treated with adjuvant chemotherapy with or without tamoxifen
Collect information regarding breast cancer risk factors treatment pathology diet activity levels weight and smoking in these patients

OUTLINE Patients are stratified according to type of treatment adjuvant chemotherapy plus tamoxifen vs adjuvant chemotherapy alone

Patients receive adjuvant chemotherapy with or without oral tamoxifen at the discretion of the treating physician

Prior to starting chemotherapy patients undergo blood draw to measure baseline levels of follicle-stimulating hormone estradiol total cholesterol high-density lipoproteins and low-density lipoproteins Patients undergo baseline bone densitometry of the femoral neck and lumbar spine to assess bone density prior to starting chemotherapy or within 30 days of the first drug treatment Laboratory studies and bone densitometry are repeated at years 1 and 2 A comparison is made between the study findings at baseline and at years 1 and 2

PROJECTED ACCRUAL A total of 80 patients 40 per stratum will be accrued for this study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NU-95B2 None None None
NCI-G00-1737 None None None